Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Radiotherapy comparisons

This article was originally published in The Gray Sheet

Executive Summary

A body of "poor quality" data suggests that head and neck cancer patients treated with radiation may experience a better quality of life following intensity-modulated radiotherapy compared to two-dimensional radiotherapy or three-dimensional conformal radiotherapy, the Agency for Healthcare Research and Quality said in a draft comparative effectiveness 1report released for comments July 24. That is the strongest statement possible based on what is largely insufficient evidence on the relative outcomes from four different head and neck cancer radiotherapy treatments, AHRQ says. Acknowledging that head and neck cancers are relatively rare, AHRQ urges more multicenter, randomized trials or at least observational studies with more prospective data. Comments are due Aug. 22

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027748

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel